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comparable to continuous intravenous therapy in 
terms of safety and efficacy in the treatment of 
severe preeclampsia. A larger scale study is 
recommended to further confirm our findings.
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ABSTRACT
Context: Magnesium sulphate is currently the drug of choice in the prevention and treatment of eclampsia. 
On-going research is addressing its administration in terms of dosage, duration and safety. 
Objective: We evaluated a modified method of magnesium sulphate administration with respect to safety, 
efficacy and maternofetal outcome.
Design, Setting And Subjects: This was a prospective cohort study conducted at the UBTH, Benin City 
with patients managed for severe preeclampsia between June and December, 2011. The Zuspan regimen 
was compared with a modified intravenous regimen in which magnesium maintenance therapy was given 
as 1g hourly bolus injection administered over 10 minutes. Both methods were evaluated for safety, efficacy 
and materno-fetal outcome. 
Result: The mean age, parity, gestational age and body mass index were 28.09±5.5 years, 2.72±1.98, 
36.67±3.54 weeks and 26.51±5.60 respectively. Both methods achieved therapeutic levels, but blood 
pressure control was better in the continuous group than the bolus group (27% vs 100%, P=0.000). Birth 
asphyxia occurred in 14.8% of the babies and was 3 times more in the continuous group (22% vs 7.5%; 
p=0.062). More babies in the bolus group were admitted to SCBU (54.1% vs 7.9%; p=0.000). There was no 
early neonatal death, and no maternal death in the first week of puerperium.
Conclusion: This study showed that hourly bolus intravenous administration of magnesium sulphate is 
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sulphate, preeclampsia, University of Benin Teaching Hospital. 
INTRODUCTION
State, Nigeria in 2008, the Population Council 
13reported a toxicity rate of less than 2% . It has 
been suggested that laboratory estimation be 
limited to cases where clinical monitors point to 
12toxicity .
In the last decade, several authors have 
described various modifications to these 
regimens, emphasizing either the dose or 
14-16duration of administration . A method 
involving bolus administration of 2g every 2 
hours was found to be inferior to the Zuspan 
17regimen . In the Department of Obstetrics and 
Gynaecology of University of Benin Teaching 
Hospital (UBTH), we have used a modification 
of Zuspan regimen in the last 5 years, with the 
maintenance given as bolus intravenous 
administration of 1g of 20% magnesium 
sulphate solution over 10 minutes every hour. 
This alternative scheme avoids the risks due to 
intramuscular magnesium sulphate and the 
difficult control with gravity-fed drip set, while 
allowing intravenous regimen in the absence of 
infusion pumps. The aim of this study was to 
assess the safety of this method and to compare 
the efficacy with that of the continuous 
intravenous regimen. The hypothesis that serum 
magnesium concentration and clinical efficacy 
of our modified regimen are similar to Zuspan's 
regimen was evaluated in this study.
MATERIALS AND METHODS
A prospective cohort study was 
conducted between June and December 2011 at 
the Obstetrics and Gynaecology Department of 
University of Benin Teaching Hospital (UBTH), 
Benin City with approval of the Institutional 
Preeclampsia remains a common cause 
of maternal and perinatal morbidity worldwide 
and a cause of mortality especially in the 
underprivileged populations. In Nigeria, it is one 
of the leading causes of maternal mortality and 
contributes significantly to perinatal morbidity 
1-5and mortality . Following the landmark reports 
of Magpie Trial and Eclampsia Trial 
Collaborative Groups, magnesium sulphate is 
now firmly established to be the drug of choice 
for the prevention and control of seizures in 
preeclampsia, resulting in more than 50% 
6-8reduction in eclampsia risk . As a corollary, 
deaths attributable to eclampsia will be 
significantly reduced by making magnesium 
sulphate widely available, accessible, affordable 
and acceptable.
9 10The Pritchard  and Zuspan  regimens of 
magnesium sulphate therapy have been in 
practice for many years, and are considered the 
11standard regimens but Sibai  has recommended 
a different regimen. Using any of the two 
standard protocols, the target serum therapeutic 
8levels of magnesium are 2.0-3.5mEq/l , while 
Sibai uses plasma levels of 4.0-8.0mg/dl during 
treatment. Safe monitoring of the patients during 
treatment can be achieved using clinical tools 
including deep tendon reflexes, respiratory rate 
and urinary output. In their work, Ekele and 
12Badung  found that the serum magnesium levels 
of eclamptic patients on treatment with 
magnesium sulphate did not exceed 3mmol/l, 
and thus concluded that routine estimation of 
serum magnesium was not necessary. While 
administering magnesium sulphate to treat 
severe preeclampsia and eclampsia in Kano 
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Review Board. The subjects were patients 
treated with magnesium sulphate(MgSO ) for 4
severe preeclampsia who were randomized to 
receive either bolus intravenous or continuous 
intravenous maintenance therapies. To achieve 
a uniform subject population, only patients with 
severe preeclampsia who booked in UBTH for 
antenatal care were included in this study. 
Postpartum cases of severe preeclampsia, 
patients with intrauterine fetal death, renal 
failure or those who had any treatment 
administered elsewhere before admission into 
UBTH were excluded. 
Participants gave consent and were 
randomized equally using sealed brown 
envelopes containing labelled cards. Subjects 
randomized to group 'A' had the bolus protocol, 
while group 'B' had continuous intravenous 
regimen. Severe preeclampsia was defined as 
diastolic blood pressure (DBP) of ≥110mmHg 
and/or systolic blood pressure (SBP) of ≥
160mmHg associated with proteinuria of at 
least 1+ on dipstick examination.
At admission, the patient was stabilized 
and preparation made for her delivery. 
Intravenous access was secured; blood was 
drawn for  serum magnesium assay,  
electrolytes, urea and creatinine estimation, full 
blood count with platelets, liver function test 
and clotting time before commencing MgSO . 4
Magnesium sulphate seizure prophylaxis was 
then commenced as outlined in the protocols 
with a bolus dose of 4g and maintenance dose of 
1g/h; the modified treatment group had 1g of 
20% solution given over 10min and repeated 
every hour for 24h, while the continuous 
intravenous group had the same 20% solution 
delivered at the rate of 1g/h as continuous 
infusion. An additional bolus intravenous dose 
of 2g was provided should there be seizure 
occurrence in both treatment groups. Treatment 
of acute rise in blood pressure was by 
intermittent slow intravenous administration of 
10mg bolus hydrallazine for both groups, and 
was required whenever the DBP was 110mmHg 
or more.
Serum magnesium (Mg) level was 
monitored after 2h and thereafter, every 6h for 
the period of the maintenance treatment.  
Additional monitoring for magnesium toxicity 
was done with assessment for loss of deep 
tendon reflex, depressed respiration to less than 
12 cycles/min, and reduced urinary output to less 
than 30 ml/hour, any of which necessitated 
withholding the next maintenance bolus dose in 
'Group A' or stopping the magnesium sulphate 
infusion in 'Group B'. All the patients were 
monitored in the labour ward for 48 hours from 
admission inclusive of the period of the 
maintenance therapy which lasted for 24 hours, 
and their babies were followed up for one week.
The primary outcome measure was the 
comparison of serum magnesium levels 
achieved by both methods of magnesium 
sulphate administration, while secondary 
endpoint was to compare clinical outcome. 
Maternal clinical outcomes compared included 
level of seizure prophylaxis, loss of knee jerk 
reflex, respiratory depression, oliguria, number 
of deferred MgSO doses. Neonatal outcome 4 
measures were stillbirth rate, Apgar scores, 
admission to special care baby unit (SCBU), 
requirement for calcium gluconate and early 
neonatal death (ENND).
In the determination of the sample size 
we assumed 58% reduction of eclampsia risk 
using the standard Zuspan regimen. Anticipating 
not more than 50% difference in the level of 
seizure prophylaxis with our current regimen, 
with a statistical power of 80%, confidence 
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interval of 90%, and the level of significance set 
at 0.05, a sample size of 50 patients in each 
group was obtained.
Five millilitres of venous blood was 
drawn for the estimation of serum magnesium 
before the loading dose of magnesium sulphate 
and then at 2 hours after the loading dose. 
Subsequently, Mg levels were done every 6 
hours while the patient was on magnesium 
sulphate (just before the next due bolus dose of 
magnesium sulphate in treatment group 'A'). 
Another sample was required if the patient had 
seizure or showed signs of magnesium toxicity. 
Blood samples for Mg estimation were 
immediately transferred to the laboratory to be 
centrifuged after clot retraction to obtain serum. 
The separated serum was then used for the 
analysis or was frozen if analysis was not 
immediately possible. Analysis was done by 
standard techniques in the clinical chemistry 
labora tory  us ing the  k i t  by  TECO 
18DIAGNOSTICS, CALIFORNIA, USA .
The generated database was analyzed 
with a personal computer using the SPSS 
version 15 and GraphPad Instat 3. Categorical 
variables were expressed as absolute numbers 
and percentages and the differences in 
proportion between the two groups were 
analyzed using the Chi square test or Fisher 
exact test where appropriate, while continuous 
variables were presented as means with 
standard deviations and the differences 
between the two groups were analyzed with the 
Student t test. The level of significance was set 
as p<0.05
RESULTS
There were 100 patients included in this 
study, 50 in each treatment arm. The age range 
was 15 to 41 years, parity range was Para “0” to 
Para 5, and the gestational age range was 26 to 41 
weeks. The mean age, parity, gestational age and 
body mass index were not significantly different 
between the two groups (Table 1). There were no 
cases of loss of knee jerk reflex, oliguria, 
deferred MgSO doses, respiratory depression or 4 
episodes of seizure recorded in both treatment 
groups. There was also no maternal death in the 
study population.
The mean serum magnesium remained 
within the therapeutic range at all times of 
nd thestimation except at the 2  and 20  hours in the 
continuous intravenous group. Mean serum 
magnesium levels were similar in the two arms 
thexcept at the 20  hour when the serum 
concentration of magnesium was 16% higher in 
the bolus intravenous group than the continuous 
intravenous group, though this difference was 
not statistically significant (2.30±1.01(SD) 
versus 1.98±0.85 mEq/L, p=0.09; Table 2). 
There was a gradual rise in the mean serum 
thmagnesium levels in both groups up to the 8  
thhour, and thereafter, a slow drop toward the 20  
hour in the continuous intravenous group while a 
second peak was observed at this time in the 
bolus group (Table 2). 
The mean DBP at admission for the two 
groups was similar; however, in the first 48 
hours on admission, there was a significant 
difference in the requirement for hydrallazine to 
control DBP. Patients treated with bolus 
intravenous therapy were about 4 times more 
likely to require 4 or more doses of hydrallazine 
than the continuous intravenous group (100% 
versus 27%, p=0.000; Table 3). Hence, there was 
a better DBP control in the continuous 
intravenous therapy group. In both arms, DBP 
thdropped significantly at the 6  hour with little 
thchange observed toward the 12  hour.  After 12 
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hours of magnesium therapy, the mean DBP in 
the bolus group was 5% higher than that of the 
continuous group (95.5 versus 90.89mmHg; 
thFigure 1). A secondary rise in DBP at the 18  
hour was observed in both groups, though this 
change was more in the bolus intravenous group 
(5% versus 15%, p=0.0013; Figure 1). 
The rate of stillbirth was the same in both 
groups. Birth asphyxia occurred in 12.0% of the 
babies and was 3 times more in the continuous 
group than the bolus group but this difference 
did not reach statistical significance (18% 
versus 6%, p=0.121; Table 4). However, the 
admission rate to SCBU did not reflect this 
difference in asphyxia rate as SCBU admission 
was 34% more in the bolus group than the 
continuous group (40% versus 6%, p=0.000). It 
is noteworthy that most of the babies were 
admitted because of prematurity and low birth 
weight (information not in table). There was no 
baby admitted to SCBU in both treatment arms 
who required calcium gluconate to treat clinical 
hypermagnesaemia. And none of the babies 
suffered early neonatal death.
DISCUSSION
The use of magnesium sulphate to treat 
severe preeclampsia has several advantages. It 
is known to reduce the risk of eclampsia by 
1958%  and also improves neonatal outcome, 
20,21especially in preterm infants . In particular, 
the use of magnesium sulphate reduces the risk 
13of maternal death  by preventing eclampsia 
which is known to increase the mortality due to 
severe preeclampsia. And this study has shown 
that therapeutic levels of Mg can be achieved 
with both continuous and bolus intravenous 
s c h e m e s  o f  m a g n e s i u m  s u l p h a t e  
administration, with comparable clinical 
outcomes for the mothers and babies in women 
with severe preeclampsia. The levels of seizure 
prophylaxis were the same for the two groups, 
though blood pressure control was better in 
subjects who had continuous intravenous 
scheme. There were no significant differences in 
the rate of stillbirth or birth asphyxia. 
The sample size of this study is large 
12,17when compared with previous works . Again, 
one major advantage over some other studies is 
that only subjects with preeclampsia were 
recruited. Considering the peculiar pathogenesis 
of the disease and its progression, ensuring a 
homogenous study population was paramount in 
the conduct of this study. And the observed 
similarity in age, parity, body mass index and 
gestational age between the two groups further 
confirmed that the results obtained were likely 
reflective of our study variable, that is, the 
method of magnesium sulphate administration. 
In order to capture the alterations in 
magnesium levels following the administration 
of the loading dose of magnesium sulphate, 
frequent collection of blood samples will be 
appropriate in the first hour, while hourly 
determination will be adequate subsequently to 
allow observation of changes to the magnesium 
level in subjects receiving bolus therapy. The 
timing of magnesium estimation in this study 
was aimed at observing the pattern of serum 
magnesium throughout the 24-hour period of 
treatment with magnesium sulphate which is 
different from the 4 hours studied by Abbade and 
17co-workers . 
22Sibai and colleagues  showed that 
Pritchard regimen which combines intravenous 
and intramuscular injection of magnesium 
sulphate was a better way to achieve therapeutic 
levels of magnesium as well as maintain a 
plateau than Zuspan scheme which recommends 
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1g per hour as continuous intravenous infusion. 
However, Sibai's modified continuous 
intravenous regimen of 2g per hour was shown 
to achieve similar serum Mg levels as the 
Pritchard regimen after 3 hours of therapy. 
17Abbade and co-workers  compared Zuspan 
scheme with a bolus intravenous scheme 
administered as 2g over 15 to 20 minutes every 
2 hours. Peak serum levels were detected at 15 
minutes in both groups; however, serum levels 
were significantly higher, plateau was 
maintained better and area under the curve was 
significantly higher in the Zuspan scheme than 
their alternate scheme. In another study, Ekele 
12and Badung  demonstrated that therapeutic 
levels were achieved with Pritchard regimen in 
19 eclamptic patients in whom they recorded a 
repeat seizure rate of 5%.  
In this study, the pattern of serum 
magnesium observed during therapy showed 
that this bolus scheme is similar to the 
continuous intravenous regimen in achieving 
therapeutic levels. This is different from the 
report of Abbade and co-workers, and may be 
explained by the frequency of administration 
employed in our study as hourly versus every 2 
hours in the former.  The higher mean serum 
nd thmagnesium level at the 2  and 20 -hour assays 
in the bolus therapy group is likely as a result of 
the high levels of magnesium achieved within 
30 minutes of a bolus dose of magnesium 
23 thsulphate . The clinical implication of the 20 -
hour secondary rise in serum magnesium level 
in the bolus therapy group is not immediately 
apparent but may be related to cardiovascular 
changes in the postpartum period. 
Prior to and during the period of this 
study, patients with acute rise in blood pressure 
were treated with intravenous hydrallazine (we 
have routinely use labetalol). The patients who 
had bolus therapy had significantly more doses 
of hydrallazine for the control of blood pressure. 
It is likely that the steady maintenance of 
magnesium level in the serum by continuous 
therapy was associated with fewer requirements 
for hydrallazine. This may be explained by the 
antihypertensive role suggested for magnesium 
sulphate by the relaxation of smooth muscle 
which might have been more sustained in the 
continuous therapy group. 
Similarly, the continuous therapy group 
was associated with faster reduction in diastolic 
blood pressure within the first 6 hours than the 
bolus group, but this finding was not statistically 
significant. In the same manner, subsequent 
blood pressure control was better in the 
continuous therapy group. In this study, a trend 
toward a secondary rise in diastolic blood 
thpressure at the 18  hour was observed in both 
treatment groups, though this rise was also more 
in the bolus group. This may be explained by the 
rise in blood pressure that is known to occur after 
rd th 24delivery and peaks at about the 3  or 4  day .
This study revealed that the neonatal 
outcome was quite favourable when patients 
with severe preeclampsia are treated with 
magnesium sulphate. There have been reports of 
adverse neonatal outcome in babies exposed to 
25magnesium sulphate in utero . However, many 
recent studies seem to suggest a protective role 
for magnesium-exposed infants, especially 
20,21when born preterm . The favourable neonatal 
outcome may be explained by this effect as well 
as the favourable mean gestational age of 36.7 
weeks at delivery. This effect was noted in the 
two treatment groups except for SCBU 
admission where the bolus therapy significantly 
contributed more babies to SCBU. Despite this 
difference in the admission rate there were no 
babies who suffered early neonatal death in both 
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groups. 
It is instructive to note that stillbirth rate 
was similar in both treatment arms. The 
presence of stillbirth appeared to be due to the 
effect of the disease on the fetuses rather than 
the method of magnesium sulphate treatment. 
Severe preeclampsia has perinatal effects 
which may show as intrauterine growth 
restriction or intrauterine fetal death. This is 
especially so when the gestational age at 
delivery is remote from term. The mean 
gestational age of our study population was 
36.7 weeks. 
CONCLUSION
Magnesium sulphate remains an 
important drug for the treatment and prevention 
of eclampsia. Hourly bolus administration of 
magnesium sulphate is a useful alternative to 
the standard Zuspan protocol where infusion 
pumps are not readily available. A multicentre 
study designed to confirm the findings of this 
study, incorporating more frequent assessment 
of serum magnesium levels to further evaluate 
the utility of hourly bolus magnesium therapy in 
severe preeclampsia is recommended.
TABLES AND FIGURES
Table 1: Maternal socio-demographic 
characteristics
Characteristic Frequency (%) P-value
Bolus (n=50) Continuous 
(n=50)


































































Table 2: Maternal serum magnesium level in 
women treated with magnesium sulphate for 
preeclampsia
Time Bolus (n=50) Continuous 
(n=50)
T value P value







































Values are in milliequivalent per litre of serum and as mean 
± SD
58
Trop J Obstet Gynaecol, 30 (1), April 2013
2. Onuh S.O, Aisien A.O. Maternal and fetal 
outcome in eclamptic patients in Benin City, 
Nigeria. J Obstet Gynaecol. 2004; 24(7): 
765–768.
3. Ekele BA, Bello SO, Adamu AN. Clusters of 
eclampsia in a Nigerian teaching hospital. 
Int. J Gynaecol Obstet 2007;96:62–6
4. Audu LR, Ekele BA. A ten year review of 
maternal mortality in Sokoto, Northern 
Nigeria. West Afr J Med 2002;21:74–6
5. Adetoro OO. A sixteen year survey of 
maternal mortality associated with 
eclampsia in Ilorin, Nigeria. Int. J Gynaecol 
Obstet 1989; 30:117–21.
6. Eclampsia Trial Collaborative Group. Which 
anticonvulsant for women with eclampsia? 
Evidence from the Collaborative Eclampsia 
Trial. Lancet. 1995; 345:1455–63. 
7. Magpie Trial Collaborative Group. Do 
women with preeclampsia and their babies 
benefit from magnesium sulphate? The 
Magpie Trial: A randomized placebo-
controlled trial. Lancet. 2002; 359:1877–90.
8. Okpere EE. Eclampsia. In: Okpere EE(ed) 
Clinical Obstetrics. UNIBEN PRESS, 2004; 
p151–157.
9. Pritchard JA, Cunningham FG, Pritchard 
SA. The Parkland Memorial Hospital 
protocol for treatment of eclampsia: 
Evaluation of 245 cases. Am J Obstet 
Gynecol. 1984; 148: 951–63.
10. Zuspan FP. Problems encountered in the 
t r e a t m e n t  o f  p r e g n a n c y - i n d u c e d  
hypertension. Am J Obstet Gynecol. 1978; 
131:591–7.
11. Sibai BM. Diagnosis, differential diagnosis, 
and management of eclampsia. Obstet 
Gynecol. 2005; 105:402–410.
12. Ekele BA, Badung SL. Is serum magnesium 
estimate necessary in patients with 
Table 3: Requirement for hydrallazine
Number of hydrallazine in first 48 hours
Total
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Table 4: Perinatal outcome following maternal 
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Abbreviation: SCBU, special care baby unit. Values are given as number (percent).
Fig. 1: Changes in diastolic blood pressure during 
treatment
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